MedTrace Logo

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

NCT04702503 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-01-11

No results posted yet for this study

Summary

Single center, pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)

Conditions

  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions

DRUG

WP1220

Topical administration 2x daily for 84 consecutive days

Sponsors & Collaborators

Principal Investigators

  • Sandra Silberman, MD, PhD · Moleculin Biotech, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-08
Primary Completion
2019-11-15
Completion
2020-11-15

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04702503 on ClinicalTrials.gov